Factoring in that patients require continual and constant monitoring, maintenance
Michelle Dalton, ELS
A phase II clinical trial evaluating suprachoroidal CLS-TA used with intravitreally administered aflibercept in patients with diabetic macular edema (DME) over a 6-month evaluation period—has met both primary and secondary endpoints of vision and anatomic improvement.
When it comes to first-line anti-vascular endothelial growth factor (VEGF) agents for the treatment of age-related macular degeneration (AMD), the overwhelming majority of retina specialists in Africa/Middle East (n = 198) and the United
A short course of oral mifepristone may reduce or improve subretinal fluid and improve best-corrected visual acuity (BCVA) in patients with chronic or recurrent central serous chorioretinopathy (CSC), said Roger Goldberg, MD, MBA, with Ba
Among the evolving trends in practice patterns of North American vitreoretinal surgery fellows from 2010 to 2018 is that fellows are reporting an increasing number of surgical cases where they are the primary surgeon, said Robert Gizicki,
Intraoperative optical coherence tomography (OCT) allows surgeons to visualize retinal anatomy and provides the surgeon with real-time feedback on instrument-tissue interaction.
With all the technological and medical advances for the treatment of diabetic eye diseases, retinal specialists still have an ongoing therapy issue because patients require continual and constant monitoring and maintenance, said Rishi P.
Treating symptomatic vitreomacular traction (VMT) with pneumatic vitreolysis and limited face-down positioning "is a highly effective emerging technique for achieving VMT release (86%) for focal VMT, with a respectable macular hole closur
Results from two large, phase III studies (HAWK and HARRIER) have found brolucizumab 6 mg (Novartis) produced better anatomical outcomes than aflibercept-in terms of retinal thickness, intraretinal fluid (IRF), and/or subretinal fluid (SR
Treating geographic atrophy (GA) with complement C3 inhibitor pegcetacoplan 15 mg (APL-2; Apellis Pharmaceuticals) resulted in slowed atrophy growth when compared with placebo at 12 months, said Nathan Steinle, MD.